Psychedelics and the future of treating substance abuse with John Lem and Timothy Ko - Toronto - Canada‘s Podcast

<p>Entheon Biomedical CEO <a href='https://www.linkedin.com/in/timothy-ko-ab982931/'>Timothy Ko</a> and <a href='https://www.linkedin.com/in/johnlem/'>John Lem</a>, the founder of <a href='https://www.lobogene.com/'>Lobo Genetics</a> are singular in their mission to research genetic driven approaches to developing personalized tools for use in psychedelic-assisted therapeutic treatments for substance use disorders.</p> <p>With firsthand knowledge of the shortcomings of the current treatment system, Ko, and Lem, the developer behind a direct-to-consumer platform being used in HaluGen’s Psychedelic Genetics test kit, the two are working together to find the right solutions for patients faster and improve outcomes.</p> <p>Entrepreneurs are the backbone of Canada’s economy. To support Canada’s businesses, subscribe to our <a href='https://www.youtube.com/canadaspodcast'>YouTube</a> channel and follow us on <a href='https://www.facebook.com/canadaspodcast/'>Facebook</a>, <a href='http://instagram.com/canadaspodcast'>Instagram</a>, <a href='https://www.linkedin.com/company/canadas-podcast/'>LinkedIn</a> and <a href='https://twitter.com/canadaspodcast'>Twitter</a>.</p> <p>Want to stay up-to-date on the latest #entrepreneur podcasts and news? <a href='https://canadaspodcast.com/newsletter-signup'>Subscribe</a> to our bi-weekly newsletter</p>